Designed to target skin cancer, the implantable vaccine opens a door to treating many cancers and inflammatory diseases
A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.
The effort is the fruit of a new model of translational research being pursued at the Wyss Institute for Biologically Inspired Engineering at Harvard University that integrates the latest cancer research with bioinspired technology development. It was led by Wyss Core Faculty member David J. Mooney, Ph.D., who is also the Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), and Wyss Institute Associate Faculty member Glenn Dranoff, M.D., who is co-leader of Dana-Farber Cancer Institute’s Cancer Vaccine Center.
Most therapeutic cancer vaccines available today require doctors to first remove the patient’s immune cells from the body, then reprogram them and reintroduce them back into the body. The new approach, which was first reported to eliminate tumors in mice in Science Translational Medicine in 2009, the year the Wyss Institute was launched, instead uses a small disk-like sponge about the size of a fingernail that is made from FDA-approved polymers. The sponge is implanted under the skin, and is designed to recruit and reprogram a patient’s own immune cells “on site,” instructing them to travel through the body, home in on cancer cells, then kill them.
The technology was initially designed to target cancerous melanoma in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression.
“Our vaccine was made possible by combining a wide range of biomedical expertise that thrives in Boston and Cambridge,” said Mooney, who specializes in the design of biomaterials for tissue engineering and drug delivery. “It reflects the bioinspired engineering savvy and technology development focus of engineers and scientists at the Wyss Institute and Harvard SEAS, as well as the immunological and clinical expertise of the researchers and clinicians at Dana-Farber and Harvard Medical School.”
“This is expected to be the first of many new innovative therapies made possible by the Wyss Institute’s collaborative model of translational research that will enter human clinical trials,” said Wyss Founding Director Don Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and a Professor of Bioengineering at Harvard SEAS. “It validates our approach, which strives to move technologies into the clinical space much faster than would be possible in a traditional academic environment. It’s enormously gratifying to see one of our first technologies take this giant leap forward.”
The Wyss Institute comprises a consortium of researchers, engineers, clinicians, and staff with industrial and business development experience from the Wyss Institute and nine other collaborating institutions in Greater Boston.
“It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Dranoff, who is also a Professor of Medicine at Harvard Medical School, and Leader of the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology. “We’re beyond thrilled with the momentum, and excited about its potential.”
The Latest on: Cancer Vaccine
- How Viruses Are Being Used to Fight Canceron July 22, 2019 at 12:02 pm
She has been testing a pancreatic cancer vaccine in patients who are eligible for complete surgical resection but are at high risk for disease recurrence. The initial studies have demonstrated the ... […]
- The vaccine that can prevent canceron July 22, 2019 at 10:06 am
This Saturday is "World Head and Neck Cancer Day". As well as including skin cancers, cancers of the nasal passages, salivary glands and other areas, the "head and neck" group also includes ... […]
- Bay Area Company Moves Forward With Development of Cancer Vaccineon July 22, 2019 at 8:08 am
TAMPA, Fla. — A Tampa-based company is moving forward with human clinical trials of a cancer vaccine. Morphogenesis, Inc. working on cancer treatment Phase one of cancer clinical trials complete 160 ... […]
- CSU scientists hope a cancer vaccine for dogs could lead to a breakthrough for humanson July 19, 2019 at 7:37 am
CSU scientists hope a cancer vaccine for dogs could lead to a breakthrough for humans The research is being conducted by Colorado State University, the University of Wisconsin-Madison and the ... […]
- Anixa Biosciences, Cleveland Clinic enter license agreement for breast cancer vaccine technologyon July 17, 2019 at 10:31 am
San Jose, Calif.-based biotechnology company Anixa Biosciences Inc. (Nasdaq: ANIX) announced Wednesday, July 17, that it has established a strategic alliance and license agreement with Cleveland ... […]
- Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technologyon July 17, 2019 at 5:47 am
Anixa to Host a Conference Call Thursday, July 18, 2019, 4:30 p.m. ET to Discuss Agreement SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company ... […]
- Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euroson July 16, 2019 at 7:58 am
A large family-owned drugmaker in Germany plans to shell out more than $350 million to buy a cancer vaccine maker in Switzerland. Ingelheim am Rhein, Germany-based Boehringer Ingelheim said Monday ... […]
- Personalized Cancer Vaccines in Clinical Trialson July 15, 2019 at 2:56 pm
In 2014, at Washington University School of Medicine in St. Louis, six melanoma patients received infusions of an anticancer vaccine composed of their own dendritic cells. Our WashU colleagues had ... […]
- In a small study, a cancer vaccine assist beats immunotherapy drugs aloneon July 15, 2019 at 3:05 am
The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than ... […]
- There's a vaccine that could vanquish cervical cancer. Why aren't we using it?on July 12, 2019 at 4:08 pm
Among humans’ greatest achievements is the ability to control and even eradicate diseases that for centuries caused wide suffering and death. Thanks to medical advances, the ancient scourge of ... […]
via Google News and Bing News